Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07098338 · ClinicalTrials.gov registry record · Phase 2

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
278
Enrollment target
20
Study locations

NCT07098338: Recruiting Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.

NCT07098338 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 278 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07098338, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
278 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.

Primary Outcome

To assess the safety and tolerability

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Ramucirumab
  • DRUG Rilvegostomig
  • DRUG Dato-DXd

Study Locations (20)

Other

  • Research Site - Nedlands
  • Research Site - Woodville
  • Research Site - Changsha
  • Research Site - Chengdu
  • Research Site - Deyang
  • Research Site - Dongguan
  • Research Site - Fuzhou
  • Research Site - Guangzhou
  • Research Site - Guangzhou
  • Research Site - Hangzhou
  • Research Site - Hefei
  • Research Site - Linyi
  • Research Site - Mianyang

California

  • Research Site - Santa Monica
  • Research Site - Santa Rosa

Georgia

  • Research Site - Atlanta

Maryland

  • Research Site - Baltimore

Texas

  • Research Site - Houston

Virginia

  • Research Site - Fairfax

Ontario

  • Research Site - Toronto

Trial Details

FieldValue
Enrollment Target 278 participants
Start Date 2025-08-07
Est. Completion 2029-04-06
Phase Phase 2
AstraZeneca

1,285 total trials

What NCT07098338 shows while recruiting

NCT07098338 is an interventional study that assigns participants to a tested intervention. The registered 278 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (57% lower).

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Ramucirumab is the first listed.

NCT07098338 names 20 study sites across 7 states, led by Other, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT07098338 about?

NCT07098338 is a clinical study titled "A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)". This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of variou...

What is the current status of trial NCT07098338?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 278 participants. The study started on 2025-08-07. Estimated completion is 2029-04-06.

What conditions does trial NCT07098338 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT07098338?

The interventions under investigation include: Ramucirumab (DRUG), Rilvegostomig (DRUG), Dato-DXd (DRUG).

Who is sponsoring clinical trial NCT07098338?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07098338 being conducted?

This trial has 20 study locations across California, Georgia, Maryland, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07098338's enrollment target sits among peer trials

278 135th of 454 higher than 320 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04586959 · 278 participants · NA

    Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer

  • NCT05010148 · 278 participants · Phase 3

    A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain

  • NCT05489237 · 278 participants · Phase 1

    First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

  • NCT05965245 · 278 participants · NA

    Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07098338

Source: ClinicalTrials.gov NCT07098338, the US trial registry maintained by the National Library of Medicine. NCT07098338 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.